Some pathogenic BRCA1 mutants do not bind BARD1

Stable Identifier
R-HSA-9663194
Type
Reaction [transition]
Species
Homo sapiens
Compartment
nucleoplasm
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Some pathogenic BRCA1 mutants do not bind BARD1
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
The heterodimerization of BRCA1 and BARD1 is mediated by sequences encompassing the N-terminal RING domains of both proteins (Wu et al. 1996, Brzovic, Rajagopal et al. 2001, Brzovic, Meza et al. 2001, Morris et al. 2002). Cancer-predisposing mutations in the RING domain of BRCA1 frequently disrupt the formation of the BRCA1:BARD1 complex.

The following BRCA1 mutants identified in cancer patients or in families with the hereditary breast and ovarian cancer syndrome were functionally tested and shown to be unable to bind to BARD1:
BRCA1 M18T (Ransburgh et al. 2010)
BRCA1 C24R (Ransburgh et al. 2010)
BRCA1 C27A (Ransburgh et al. 2010)
BRCA1 T37R (Ransburgh et al. 2010)
BRCA1 C39Y (Ransburgh et al. 2010)
BRCA1 H41A (Ransburgh et al. 2010)
BRCA1 H41R (Ransburgh et al. 2010)
BRCA1 C44F (Ransburgh et al. 2010)
BRCA1 C47G (Ransburgh et al. 2010)
BRCA1 C61G (Wu et al. 1996, Ransburgh et al. 2010)
BRCA1 C64G (Wu et al. 1996, Ransburgh et al. 2010)
BRCA1 C64R (Caleca et al. 2014).

The following BRCA1 mutants were identified in cancer and predicted to be pathogenic. They are annotated as candidate mutants for BARD1 binding deficiency based on sequence similarity with the functionally characterized missense mutants (the same amino acid residue affected by a missense mutation as in a missense mutant shown to be unable to bind to BARD1) or based on the truncation of the RING domain due to frameshift mutations:
BRCA1 C24F
BRCA1 H41Q
BRCA1 C61Y
BRCA1 Q12Tfs*5
BRCA1 E23Afs*18
BRCA1 E23Rfs*18
BRCA1 E23Vfs*17
Literature References
PubMed ID Title Journal Year
24516540 Characterization of an Italian founder mutation in the RING-finger domain of BRCA1

Bernard, L, Zaffaroni, D, Colombo, M, Sarkar, M, Congregati, C, Magliery, TJ, Ripamonti, CB, Papi, L, Barile, M, Pensotti, V, Peissel, B, Manoukian, S, Tondini, C, Caleca, L, Foglia, C, Radice, P, Putignano, AL

PLoS ONE 2014
11573085 Structure of a BRCA1-BARD1 heterodimeric RING-RING complex

King, MC, Hoyt, DW, Rajagopal, P, Brzovic, PS, Klevit, RE

Nat. Struct. Biol. 2001
11526114 BRCA1 RING domain cancer-predisposing mutations. Structural consequences and effects on protein-protein interactions

Meza, JE, Brzovic, PS, Klevit, RE, King, MC

J. Biol. Chem. 2001
8944023 Identification of a RING protein that can interact in vivo with the BRCA1 gene product

Phung, A, Bowcock, AM, Wu, LC, Hwang, LY, Wang, ZW, Baer, R, Yang, MC, Spillman, MA, Xu, XL, Tsan, JT

Nat. Genet. 1996
20103620 Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination

Ishioka, C, Toland, AE, Ransburgh, DJ, Parvin, JD, Chiba, N

Cancer Res. 2010
Participants
Input
Participates
as an event of
Normal reaction
BRCA1 forms a heterodimer with BARD1 (Homo sapiens)
Functional status

Loss of function of BRCA1 mutants (BARD1 binding) [nucleoplasm]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Orlic-Milacic, M  (2020-09-30)
Reviewed
Baer, RJ  (2020-11-04)
Created
Orlic-Milacic, M  (2019-09-27)
Cite Us!